IP Library › Granted Patent US 11,701,434
Granted Patent B2
US 11,701,434 · App. 17/347,498 · Granted Jul 18, 2023

Tertiary amino lipidated cationic peptides for nucleic acid delivery

Inventor: Colin James McKinlay (Fremont, CA)
Assignee: NUTCRACKER THERAPEUTICS, INC.
A61K48/0041A61K9/5123A61K9/5146A61K31/7105A61K47/10A61K47/543C07K2/00C07K7/06C07K7/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,701,434
App. No.
17/347,498
Granted
Jul 18, 2023
Kind
B2
Abstract

The present disclosure relates to tertiary amino lipidated and/or PEGylated cationic peptide compounds and complexes thereof with nucleic acids for endocellular delivery, methods for preparing the compounds and complexes, and methods for delivering polyanionic compounds to cells.

Claims (43)

1. A tertiary amino lipidated and/or PEGylated cationic peptide compound of formula (I) or a salt thereof:

wherein:

s is an integer from 1 to 5;

R 1 is —H

each R 3 is independently selected from C 8 -C 24 alkyl;

R 5 is selected from hydroxyalkyl, hydroxyether, and hydroxylheteroalkyl;

R 7 is —H, alkyl, acyl, —OH, —OR 7a , —NH 2 , -NHR 7a , or a lipid moiety, wherein

R 7a is alkyl, acyl, or a lipid moiety; and

each R a and R b are independently —H, C 1 -C 4 -alkyl, or a side chain moiety found on a naturally- or non-naturally-occurring amino acid.

2. The tertiary amino lipidated and/or PEGylated cationic peptide compound of claim 1 , wherein s is 3 or 4.

3. The tertiary amino lipidated and/or PEGylated cationic peptide compound of claim 1 , wherein each R 3 is independently C 8 -C 12 alkyl.

4. The tertiary amino lipidated and/or PEGylated cationic peptide compound of claim 1 , wherein each R 3 is independently selected from the group consisting of

5. The tertiary amino lipidated and/or PEGylated cationic peptide compound of claim 1 , wherein each R 3 is independently selected from the group consisting of

6. The tertiary amino lipidated and/or PEGylated cationic peptide compound of claim 1 , wherein R a and R b are —H.

7. A complex comprising one or more of the tertiary amino lipidated and/or PEGylated cationic peptide compounds of claim 1 , complexed to a polyanionic compound.

8. The complex of claim 7 , wherein the polyanionic compound comprises a nucleic acid.

9. The complex of claim 7 , wherein the polyanionic compound comprises an mRNA encoding a polypeptide.

10. The complex of claim 7 , wherein the polyanionic compound comprises a nucleic acid and wherein the one or more tertiary amino lipidated and/or PEGylated cationic peptide compounds and the nucleic acid are present in the complex at a mass ratio between 0.5:1 and 50:1.

11. The complex of claim 7 , wherein the complex comprises: the one or more tertiary amino lipidated and/or PEGylated cationic peptide compounds, a nucleic acid, a phospholipid, a structural lipid, and a PEG lipid.

12. A method of delivering a polyanionic compound to a cell comprising contacting the cell with the complex of claim 7 .

13. The method of claim 12 , wherein the polyanionic compound comprises an mRNA encoding a polypeptide and the cell expresses the polypeptide after being contacted with the complex.

14. A method of forming the complex of claim 7 , comprising contacting the one or more tertiary amino lipidated and/or PEGylated cationic peptide compounds with the polyanionic compound.

15. The tertiary amino lipidated and/or PEGylated cationic peptide compound of claim 1 , wherein R 7 is NH 2 .

16. The tertiary amino lipidated and/or PEGylated cationic peptide compound of claim 1 , wherein s is 4 and:

two R 3 are

 and two R 3 are

 or

each R 3 is

17. The tertiary amino lipidated and/or PEGylated cationic peptide compound of claim 1 , wherein R 5 is hydroxyalkyl or hydroxyether.

18. The tertiary amino lipidated and/or PEGylated cationic peptide compound of claim 17 , wherein R 5 is hydroxyalkyl.

19. The tertiary amino lipidated and/or PEGylated cationic peptide compound of claim 18 , wherein R 5 is

20. The tertiary amino lipidated and/or PEGylated cationic peptide compound of claim 1 , wherein s is 4; each R 3 independently is

R 5 is hydroxyalkyl; R 7 is NH 2 ; and each R a and R b independently is H.

21. The tertiary amino lipidated and/or PEGylated cationic peptide compound of claim 20 , wherein each R 3 independently is

22. The tertiary amino lipidated and/or PEGylated cationic peptide compound of claim 1 , wherein the compound of formula (I) is

23. The tertiary amino lipidated and/or PEGylated cationic peptide compound of claim 5 , wherein each R 3 is

24. The tertiary amino lipidated and/or PEGylated cationic peptide compound of claim 17 wherein R 5 is

25. The tertiary amino lipidated and/or PEGylated cationic peptide compound of claim 23 , wherein R 5 is

26. The tertiary amino lipidated and/or PEGylated cationic peptide compound of claim 1 , wherein s is 4; each R 3 independently is

R 5 is

R 7 is NH 2 ; and each R a and R b is H.

27. The tertiary amino lipidated and/or PEGylated cationic peptide compound of claim 25 , wherein each R 3 is

28. The tertiary amino lipidated and/or PEGylated cationic peptide compound of claim 25 , wherein R 5 is

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 5, 2026
From: NUTCRACKER THERAPEUTICS, INC.
To: MEDICI THERAPEUTICS, INC.
Reel/Frame 074407/0450 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 16, 2021
From: MCKINLAY, COLIN JAMES
To: NUTCRACKER THERAPEUTICS, INC.
Reel/Frame 056568/0068 →
Continuity (4)
Continuation 17279508
Provisional Application 62885036 · Aug 9, 2019
Provisional Application 62738717 · Sep 28, 2018
Related Publication 20210371458A1 · Dec 2, 2021